Association of the Primary Aldosteronism Severity Classification with Lateralization and Treatment Outcomes: A Comprehensive Review

MedXY Editorial Team•Jul 3, 2026•Clinical Updates

The Primary Aldosteronism Severity Classification (PASC) significantly correlates with AVS-defined lateralization, with severity reflecting increasing unilateral aldosterone excess.
Surgical and medical treatment outcomes vary by PASC severity; higher severity is associated with lower rates of complete clinical success despite similar biochemical remission rates.
Emerging hormonal biomarkers (e.g., metanephrine, androstenedione) and imaging modalities (68Ga-pentixafor PET/CT) show promise in enhancing AVS accuracy and subtype diagnosis.
Integration of PASC with AVS results may guide individualized diagnostic and therapeutic strategies, optimizing patient outcomes in PA.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

The Primary Aldosteronism Severity Classification (PASC) significantly correlates with AVS-defined lateralization, with severity reflecting increasing unilateral aldosterone excess.
Surgical and medical treatment outcomes vary by PASC severity; higher severity is associated with lower rates of complete clinical success despite similar biochemical remission rates.
Emerging hormonal biomarkers (e.g., metanephrine, androstenedione) and imaging modalities (68Ga-pentixafor PET/CT) show promise in enhancing AVS accuracy and subtype diagnosis.
Integration of PASC with AVS results may guide individualized diagnostic and therapeutic strategies, optimizing patient outcomes in PA.